Stock of Crinetics Pharmaceuticals, Inc. (CRNX) is rising over 17 percent on Tuesday following the announcement of positive results from Phase 3 PATHFNDR-2 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
The company stated that statistical significance of primary and secondary endpoints were met in the study.
Crinetics also said that it plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2024.
Currently, Crinetics' stock is rising 17.32 percent, to $44.50 over the previous close of $37.93 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.